Targeting different types of human meningioma and glioma cells using a novel adenoviral vector expressing GFP-TRAIL fusion protein from hTERT promoter

[1]  P. Lowenstein,et al.  Gene therapy and virotherapy: novel therapeutic approaches for brain tumors. , 2010, Discovery medicine.

[2]  R. Gerard,et al.  Retargeting Adenoviral Vectors to Improve Gene Transfer into Tumors , 2010, Cancer Gene Therapy.

[3]  M. Hashizume,et al.  Combination with low-dose gemcitabine and hTERT-promoter-dependent conditionally replicative adenovirus enhances cytotoxicity through their crosstalk mechanisms in pancreatic cancer. , 2010, Cancer letters.

[4]  R. Gerard,et al.  Adenoviral Targeting of Gene Expression to Tumors , 2010, Cancer Gene Therapy.

[5]  Shu Zheng,et al.  Potent antitumor activity of double‐regulated oncolytic adenovirus‐mediated ST13 for colorectal cancer , 2009, Cancer science.

[6]  R. Herbst,et al.  To kill a tumor cell: the potential of proapoptotic receptor agonists. , 2008, The Journal of clinical investigation.

[7]  Q. Qian,et al.  Telomerase-specific oncolytic virotherapy for human hepatocellular carcinoma. , 2008, World Journal of Gastroenterology.

[8]  J. D. Young,et al.  Optimization of adenoviral vector-mediated transgene expression in the canine brain in vivo, and in canine glioma cells in vitro. , 2007, Neuro-oncology.

[9]  B. Aggarwal,et al.  Receptor-Mediated Choreography of Life and Death , 2003, Journal of Clinical Immunology.

[10]  J. Gu,et al.  Cell to cell contact required for bystander effect of the TNF-related apoptosis-inducing ligand (TRAIL) gene. , 2003, International journal of oncology.

[11]  J. Gu,et al.  Telomerase Promoter-Driven Cancer Cell Suicide , 2003, Cancer biology & therapy.

[12]  M. Xiong,et al.  Long-term tumor-free survival from treatment with the GFP–TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells , 2002, Oncogene.

[13]  M. Berger,et al.  Epidemiology of primary brain tumors: current concepts and review of the literature. , 2002, Neuro-oncology.

[14]  Steven A Curley,et al.  Targeted expression of green fluorescent protein/tumor necrosis factor-related apoptosis-inducing ligand fusion protein from human telomerase reverse transcriptase promoter elicits antitumor activity without toxic effects on primary human hepatocytes. , 2002, Cancer research.

[15]  I. Germano,et al.  Caspase-8 gene therapy using the human telomerase reverse transcriptase promoter for malignant glioma cells. , 2002, Human gene therapy.

[16]  T. Griffith,et al.  Suppression of tumor growth following intralesional therapy with TRAIL recombinant adenovirus. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[17]  S. Srinivasula,et al.  Treatment of malignant glioma cells with the transfer of constitutively active caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter. , 2001, Cancer research.

[18]  S. Curley,et al.  Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. , 2001, Cancer research.

[19]  J. Gu,et al.  Augmenting transgene expression from carcinoembryonic antigen (CEA) promoter via a GAL4 gene regulatory system. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[20]  J. Gu,et al.  Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers. , 2000, Cancer research.

[21]  B. Davidson,et al.  Adenoviral-Mediated Transfer of the TNF-Related Apoptosis-Inducing Ligand/Apo-2 Ligand Gene Induces Tumor Cell Apoptosis1 , 2000, The Journal of Immunology.

[22]  S. Strom,et al.  Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand , 2000, Nature Medicine.

[23]  G. Fuller,et al.  Intracranial injection of human meningioma cells in athymic mice: an orthotopic model for meningioma growth. , 2000, Journal of neurosurgery.

[24]  R. Weinberg,et al.  Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase , 1998, Oncogene.

[25]  J. Roth,et al.  Evaluation of GAL4/TATA in Vivo , 1998, The Journal of Biological Chemistry.

[26]  D. Bowtell,et al.  Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types. , 1997, Human molecular genetics.

[27]  R. Weinberg,et al.  The catalytic subunit of yeast telomerase. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[28]  B. Trapnell,et al.  Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy , 1996, Journal of virology.

[29]  et al.,et al.  The RNA component of human telomerase , 1995, Science.

[30]  C B Harley,et al.  Specific association of human telomerase activity with immortal cells and cancer. , 1994, Science.

[31]  C. Harley,et al.  Telomeres shorten during ageing of human fibroblasts , 1990, Nature.

[32]  M. Dempster,et al.  Human telomeres contain at least three types of G-rich repeat distributed non-randomly. , 1989, Nucleic acids research.

[33]  P. Fisher,et al.  Developing an effective gene therapy for prostate cancer: New technologies with potential to translate from the laboratory into the clinic. , 2011, Discovery medicine.

[34]  鬼丸 学.  hTERT-promoter-dependent oncolytic adenovirus enhances the transduction and therapeutic efficacy of replication-defective adenovirus vectors in pancreatic cancer cells , 2010 .

[35]  B. McCarthy,et al.  Temporal trends in incidence of primary brain tumors in the United States, 1985-1999. , 2006, Neuro-oncology.

[36]  B. Fang,et al.  [Activity of the TNF-related apoptosis-inducing ligand gene expressed from the hTERT promoter on colon cancer cell line HT-29]. , 2006, Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences.

[37]  B. Fang,et al.  hTERT promoter induces tumor-specific Bax gene expression and cell killing in syngenic mouse tumor model and prevents systemic toxicity , 2002, Gene Therapy.

[38]  V A Zakian,et al.  Structure and function of telomeres. , 1989, Annual review of genetics.